("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, presented 2 posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting held on October 13-16, 2023 in Vancouver, BC, Canada. Both posters will be ava...
资料来源:1.Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients with Hypoparathyroidism and Favorable Bone Effects of Eneboparatide at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting | Amolyt Pharma发布...
The ASBMR Annual Meeting is the world’s largest and most diverse meeting in the bone, mineral and musculoskeletal research field, attracting more than 2,000 attendees from more than 60 countries, including clinicians and researchers, representing all career levels and specializing in a variety of ...
NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) --Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be p...
開發者表明The American Society for Bone And Mineral Research的私隱慣例或包括下列資料的處理。詳情請參閱開發者的私隱政策。 與你連結的資料 開發者可能會收集以下資料並連結你的個人身份: 聯絡資料 用户內容 識別碼 使用資料 不會與你連結的資料 開發者可能會收集以下資料,但不會連結你的個人身份: ...
This review is an adapted version of the Louis V Avioli lecture, delivered at the Annual Scientific Meeting of the American Society of Bone and Mineral Research in 2023. It outlines the history of the coupling concept, details how coupling is thought to occur within tr...
(Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation atThe American Society for Bone and Miner...